A PHASE II, MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY AND OPEN-LABEL LONG TERM EXTENSION TO EVALUATE THE SAFETY AND EFFICACY OF ELAFIBRANOR IN ADULT PARTICIPANTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC)

Registry ID

CLIN-60190-453

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

IPSEN BIOSCIENCE INC

Start date

2023-08-14

Last update

2022-12-08

Conditions

• PRIMARY SCLEROSING CHOLANGITIS (PSC)

Related clinical trials

• A RANDOMIZED DOUBLE-BLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VOLIXIBAT IN THE TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (VISTAS)

View on source registry